阅读说明：本技术 作为kcnq增强剂的1-((2-(2,2,2-三氟乙氧基)吡啶-4-基)甲基)脲衍生物 (1- ((2- (2,2, 2-trifluoroethoxy) pyridin-4-yl) methyl) urea derivatives as KCNQ enhancers ) 是由 H.J.塞克雷斯 A.C.威廉姆斯 M.A.沃顿 于 2020-02-04 设计创作，主要内容包括：本申请涉及钾通道的小分子增强剂(例如Kv7增强剂——也称为KCNQ增强剂)、包含此类化合物的组合物,以及使用此类化合物治疗由运动神经元兴奋性变化引起的肌萎缩性侧索硬化和其它神经系统疾病的方法,所述疾病包括但不限于原发性侧索硬化、假性延髓麻痹、进行性延髓麻痹、进行性肌肉萎缩和癫痫。(The present application relates to small molecule enhancers of potassium channels (e.g., Kv7 enhancers, also known as KCNQ enhancers), compositions comprising such compounds, and methods of using such compounds to treat amyotrophic lateral sclerosis and other neurological diseases caused by motor neuron excitatory changes, including, but not limited to, primary lateral sclerosis, pseudobulbar palsy, progressive bulbar palsy, progressive muscle atrophy, and epilepsy.)